United Therapeutics Corporation (UTHR) stock has risen 7.60% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.
United Therapeutics Corporation has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on UTHR!
What is Stock Sentiment?
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With UTHR Stock Today?
United Therapeutics Corporation (UTHR) stock is up 0.2% while the S&P 500 is down -1.47% as of 11:58 AM on Tuesday, Jan 18. UTHR is up $0.42 from the previous closing price of $213.96 on volume of 166,484 shares. Over the past year the S&P 500 has risen 20.94% while UTHR is up 24.92%. UTHR earned $9.86 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 21.71.
More About United Therapeutics Corporation
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for pulmonary arterial hypertension largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Nearly all of its sales are generated within the United States. United also markets a pediatric oncology drug, but its focus largely remains in pulmonary hypertension.
Click Here to get the full Stock Report for United Therapeutics Corporation stock.